Shares of Ariad Pharmaceuticals Inc. (biotech ticker:ARIA) rose as much as 10% to 2.16 in early hour trading on Monday and settled 2.08 (7%) at end of trading day after analysis stated the company’s leading multi-treatment drug candidate, Ridaforolimus has good prospects for eventual FDA approval. Also, Oppenheimer initiated the stock with an "Outperform" rating and a $4 price target.
Shares of Protalix Biotherapeutics Inc (biotech ticker:PLX) up 30% pre-market trading and settled at 6.39 from Friday close of 5.77, after FDA approved treatment protocol for Gaucher disease drug.
Keryx Biopharmaceuticals, Inc. (biotech ticker:KERX) shares also climbed in that latter day of trading and closed up 8% at 1.46. The company freed up 13.4million in cash from cost cutting in operating expenses and from other security investments. Also, the company leading drug candidate, Periforisine; treatment for Multiple Myeloma, received FDA nod for the critical phase III trial protocols.
BioSante Pharmaceuticals, Inc. (biotech ticker:BPAX) shares rose 25% in early trading after company said that its adjuvant increased the efficacy of vaccines designed to guard against various flu strains, including swine flu
Vion Pharmaceuticals, Inc. (biotech ticker:VION) shares up 5% as investors speculate on the September 1st Oncologic Drugs Advisory Committee (ODAC) vote for their cancer treating drug Onrigin(TM).
Monday, August 17, 2009
Subscribe to:
Post Comments (Atom)
Posts
Theirs no end to many of these stocks
ReplyDelete